beta-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: An update - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue European Journal of Medicinal Chemistry Année : 2014

beta-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: An update

Résumé

The design of novel antitumor agents allowing the destruction of malignant cells while sparing healthy tissues is one of the major challenges in medicinal chemistry. In this context, the use of non-toxic prodrugs programmed to be selectively activated by beta-glucuronidase present at high concentration in the microenvironment of most solid tumors has attracted considerable attention. This review summarizes the major progresses that have been realized in this field over the past ten years. This includes the new prodrugs that have been designed to target a wide variety of anticancer drugs, the prodrugs employed in the course of a combined therapy, the dendritic glucuronide prodrugs and the concept of beta-glucuronidase-responsive albumin binding prodrugs.

Domaines

Chimie organique
Fichier non déposé

Dates et versions

hal-01196935 , version 1 (10-09-2015)

Identifiants

Citer

Isabelle Tranoy-Opalinski, Thibaut Legigan, Romain Barat, Jonathan Clarhaut, Mikael Thomas, et al.. beta-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: An update. European Journal of Medicinal Chemistry, 2014, 74, pp.302-313. ⟨10.1016/j.ejmech2013.12.045⟩. ⟨hal-01196935⟩
127 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More